Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Advagraf

Advagraf 0.5 mg prolonged-release hard capsules Advagraf 1 mg prolonged-release hard capsules Advagraf 3 mg prolonged-release hard capsules Advagraf 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 10–11

HOS-116802 · Präparat HOS-094481

10 Drug/Substance Class or Drug interaction effect Recommendations concerning Name co-administration Strong CYP3A4 inhibitors: May increase tacrolimus whole It is recommended that antifungal agents (e.g., blood trough concentrations and concomitant use should be ketoconazole, itraconazole, increase the risk of serious adverse avoided. If co-administration posaconazole, voriconazole), reactions (e.g., nephrotoxicity, of a strong CYP3A4 inhibitor the macrolide antibiotics neurotoxicity, QT prolongation) is unavoidable, consider (e.g., telithromycin, which requires close monitoring omitting the dose of tacrolimus troleandomycin, [see section 4.4]. the day the strong CYP3A4 clarithromycin, josamycin), Rapid and sharp increases in inhibitor is initiated. Reinitiate HIV protease inhibitors tacrolimus levels may occur, as tacrolimus the next day at a (e.g., ritonavir, nelfinavir, early as within 1-3 days after co- reduced dose based on saquinavir), HCV protease administration, despite immediate tacrolimus blood inhibitors (e.g., telaprevir, reduction of tacrolimus dose. concentrations. Changes in boceprevir, and the Overall tacrolimus exposure may both tacrolimus dose and/or combination of ombitasvir increase > 5 fold. When ritonavir dosing frequency should be and paritaprevir with combinations are co-administered, individualized and adjusted as ritonavir, when used with tacrolimus exposure may increase needed based on tacrolimus and without dasabuvir), > 50 fold. Nearly all patients may trough concentrations, which nefazodone, the require a reduction in tacrolimus should be assessed at initiation, pharmacokinetic enhancer dose and temporary interruption of monitored frequently cobicistat, and the kinase tacrolimus may also be necessary. throughout (starting within the inhibitors idelalisib, The effect on tacrolimus blood first few days) and re- ceritinib. concentrations may remain for evaluated on and after Strong interactions have also several days after co-administration completion of the CYP3A4 been observed with the is completed. inhibitor. Upon completion, macrolide antibiotic appropriate dose and dosing erythromycin frequency of tacrolimus should be guided by tacrolimus blood concentrations. Monitor renal function, ECG for QT prolongation, and other side effects closely. Moderate or weak CYP3A4 May increase tacrolimus whole Monitor tacrolimus whole inhibitors: blood trough concentrations and blood trough concentrations antifungal agents (e.g., increase the risk of serious adverse frequently, starting within the fluconazole, isavuconazole, reactions (e.g., neurotoxicity, QT first few days of co- clotrimazole, miconazole), prolongation) [see section 4.4]. A administration. Reduce the macrolide antibiotics rapid increase in tacrolimus level tacrolimus dose if needed [see (e.g., azithromycin), calcium may occur. section 4.2]. Monitor renal channel blockers (e.g., function, ECG for QT nifedipine, nicardipine, prolongation, and other side diltiazem, verapamil), effects closely. amiodarone, danazol, ethinylestradiol, lansoprazole, omeprazole, the HCV antivirals elbasvir/grazoprevir and glecaprevir/pibrentasvir, the CMV antiviral letermovir, and the tyrosine kinase inhibitors nilotinib, crizotinib and imatinib and (Chinese) herbal remedies containing extracts of Schisandra sphenanthera

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) letermovir (HOS-090621) ceritinib (HOS-086215) josamycin (HOS-113844) diltiazem (HOS-086288) nefazodone (HOS-084519) elbasvir (HOS-108814) isavuconazole (HOS-085186) nifedipine (HOS-086289) nelfinavir (HOS-084520) nicardipine (HOS-090619) protease (HOS-085623) ketoconazole (HOS-084513) pibrentasvir (HOS-086298) crizotinib (HOS-116818) cobicistat (HOS-088111) glecaprevir (HOS-086297) azithromycin (HOS-088112) clotrimazole (HOS-090574) calcium (HOS-085615) imatinib (HOS-110212) dasabuvir (HOS-110302) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) grazoprevir (HOS-108815) itraconazole (HOS-084516) saquinavir (HOS-084522) danazol (HOS-085473) fluconazole (HOS-087945) ombitasvir (HOS-110300) boceprevir (HOS-090617) clarithromycin (HOS-084517) erythromycin (HOS-084514) troleandomycin (HOS-090575) ritonavir (HOS-084521) amiodarone (HOS-085596) paritaprevir (HOS-110301) tyrosine (HOS-108875) posaconazole (HOS-085622) nilotinib (HOS-086218) miconazole (HOS-115630) idelalisib (HOS-116811) omeprazole (HOS-085912) verapamil (HOS-090602)

Wechselwirkungen · Modigraf

Modigraf 0.2 mg granules for oral suspension Modigraf 1 mg granules for oral suspension · Abschnitt 4.5 · PDF-Seite 10–11

HOS-209742 · Präparat HOS-154375

10 Medicinal products which have effects on tacrolimus Drug/Substance Class or Drug interaction effect Recommendations concerning co- Name administration Grapefruit or grapefruit juice May increase tacrolimus Avoid grapefruit or grapefruit whole blood trough juice. concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see section 4.4]. Ciclosporin May increase tacrolimus The simultaneous use of whole blood trough ciclosporin and tacrolimus should concentrations. In addition, be avoided [see section 4.4]. synergistic/additive nephrotoxic effects can occur. Products known to have May enhance nephrotoxic or Concurrent use of tacrolimus with nephrotoxic or neurotoxic neurotoxic effects of drugs known to have nephrotoxic effects: tacrolimus. effects should be avoided. When aminoglycosides, gyrase co-administration cannot be inhibitors, vancomycin, avoided, monitor renal function sulfamethoxazole + and other side effects and adjust trimethoprim, NSAIDs, tacrolimus dose if needed. ganciclovir, acyclovir, amphotericin B, ibuprofen cidofovir, foscarnet Strong CYP3A4 inhibitors: May increase tacrolimus It is recommended that antifungal agents (e.g., whole blood trough concomitant use should be ketoconazole, itraconazole, concentrations and increase avoided. If co-administration of a posaconazole, voriconazole), the risk of serious adverse strong CYP3A4 inhibitor is the macrolide antibiotics reactions (e.g., unavoidable, consider omitting (e.g., telithromycin, nephrotoxicity, the dose of tacrolimus the day the troleandomycin, neurotoxicity, QT strong CYP3A4 inhibitor is clarithromycin, josamycin), prolongation) which requires initiated. Reinitiate tacrolimus the HIV protease inhibitors (e.g., close monitoring [see next day at a reduced dose based ritonavir, nelfinavir, section 4.4]. on tacrolimus blood saquinavir), HCV protease Rapid and sharp increases in concentrations. Changes in both inhibitors (e.g., telaprevir, tacrolimus levels may occur, tacrolimus dose and/or dosing boceprevir, and the as early as within 1-3 days frequency should be combination of ombitasvir after co-administration, individualized and adjusted as and paritaprevir with despite immediate reduction needed based on tacrolimus ritonavir, when used with and of tacrolimus dose. Overall trough concentrations, which without dasabuvir), tacrolimus exposure may should be assessed at initiation, nefazodone, the increase > 5 fold. When monitored frequently throughout pharmacokinetic enhancer ritonavir combinations are (starting within the first few days) cobicistat and the kinase co-administered, tacrolimus and re-evaluated on and after inhibitors idelalisib, ceritinib. exposure may increase > 50 completion of the CYP3A4 Strong interactions have also fold. inhibitor. Upon completion, been observed with the Nearly all patients may appropriate dose and dosing macrolide antibiotic require a reduction in frequency of tacrolimus should be erythromycin tacrolimus dose and guided by tacrolimus blood temporary interruption of concentrations. Monitor renal tacrolimus may also be function, ECG for QT necessary. prolongation, and other side effects closely.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): foscarnet (HOS-110484) sulfamethoxazole (HOS-084533) ceritinib (HOS-086215) josamycin (HOS-113844) nefazodone (HOS-084519) nelfinavir (HOS-084520) ibuprofen (HOS-087884) protease (HOS-085623) amphotericin B (HOS-109312) trimethoprim (HOS-085184) ketoconazole (HOS-084513) cobicistat (HOS-088111) cidofovir (HOS-110482) grapefruit juice (HOS-088787) dasabuvir (HOS-110302) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) ombitasvir (HOS-110300) boceprevir (HOS-090617) clarithromycin (HOS-084517) vancomycin (HOS-110486) erythromycin (HOS-084514) troleandomycin (HOS-090575) ritonavir (HOS-084521) ganciclovir (HOS-085194) paritaprevir (HOS-110301) acyclovir (HOS-088527) posaconazole (HOS-085622) idelalisib (HOS-116811)

Gegenanzeigen · Zydelig

Zydelig 100 mg film-coated tablets Zydelig 150 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 4

HOS-132090 · Präparat HOS-097192

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Zydelig

Zydelig 100 mg film-coated tablets Zydelig 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6

HOS-132091 · Präparat HOS-097192

Idelalisib is metabolised primarily via aldehyde oxidase, and to a lesser extent via CYP3A and glucuronidation (UGT1A4). Its primary metabolite is GS-563117, which is not pharmacologically active. Idelalisib and GS-563117 are substrates of P-gp and BCRP.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Zydelig

Zydelig 100 mg film-coated tablets Zydelig 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6–7

HOS-132092 · Präparat HOS-097192

6 Effect of other medicinal products on idelalisib pharmacokinetics

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Zydelig

Zydelig 100 mg film-coated tablets Zydelig 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-132093 · Präparat HOS-097192

CYP3A inducers A clinical drug interaction study found that co-administration of a single dose of 150 mg idelalisib with rifampicin (a strong CYP3A inducer) resulted in a ~75% reduction in idelalisib AUCinf. Co-administration of Zydelig with moderate or strong CYP3A inducers such as rifampicin, phenytoin, St. John’s wort, or carbamazepine should be avoided as this may result in decreased efficacy.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carbamazepine (HOS-085618) phenytoin (HOS-084531)

Wechselwirkungen · Zydelig

Zydelig 100 mg film-coated tablets Zydelig 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-132094 · Präparat HOS-097192

CYP3A/P-gp inhibitors A clinical drug interaction study found that co-administration of a single dose of 400 mg idelalisib with 400 mg once daily ketoconazole (a strong CYP3A, P-gp and BCRP inhibitor) resulted in a 26% increase in Cmax and a 79% increase in AUCinf of idelalisib. No initial dose adjustment of idelalisib is considered necessary when administered with CYP3A/P-gp inhibitors, but an intensified monitoring of adverse reactions is recommended.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513)

Wechselwirkungen · Zydelig

Zydelig 100 mg film-coated tablets Zydelig 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-132095 · Präparat HOS-097192

Effect of idelalisib on the pharmacokinetics of other medicinal products

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Zydelig

Zydelig 100 mg film-coated tablets Zydelig 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-132096 · Präparat HOS-097192

CYP3A substrates The primary metabolite of idelalisib, GS-563117, is a strong CYP3A inhibitor. A clinical drug interaction study found that co-administration of idelalisib with midazolam (a sensitive CYP3A substrate) resulted in a ~140% increase in Cmax and a ~440% increase in AUCinf of midazolam due to the CYP3A inhibition by GS-563117. Co-administration of idelalisib with CYP3A substrates may increase their systemic exposures and increase or prolong their therapeutic activity and adverse reactions. In vitro, the CYP3A4 inhibition was irreversible, and return to normal enzyme activity is therefore expected to take several days after stopping idelalisib administration.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): midazolam (HOS-086167)

Wechselwirkungen · Zydelig

Zydelig 100 mg film-coated tablets Zydelig 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-132097 · Präparat HOS-097192

Potential interactions between idelalisib and co-administered medicinal products that are CYP3A substrates are listed in Table 1 (increase is indicated as “↑”). This list is not exhaustive and is intended to serve as guidance only. In general, the SmPC for the other product must be consulted for the recommendations regarding co-administration with CYP3A4 inhibitors (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Zydelig

Zydelig 100 mg film-coated tablets Zydelig 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-132098 · Präparat HOS-097192

Table 1: Interactions between idelalisib and other medicinal products that are CYP3A substrates

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Zydelig

Zydelig 100 mg film-coated tablets Zydelig 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-132099 · Präparat HOS-097192

Medicinal product Expected effect of Clinical recommendation upon idelalisib on medicinal co-administration with idelalisib product levels ALPHA-1 ADRENORECEPTOR ANTAGONISTS Alfuzosin ↑ serum concentrations Idelalisib should not be co-administered with alfuzosin. ANALGESICS Fentanyl, alfentanil, methadone, ↑ serum concentrations Careful monitoring of adverse buprenorphine/naloxone reactions (e.g., respiratory depression, sedation) is recommended. ANTIARRHYTHMICS Amiodarone, quinidine ↑ serum concentrations Idelalisib should not be co-administered with amiodarone or quinidine.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) alfuzosin (HOS-086139) methadone (HOS-086198) quinidine (HOS-085593) buprenorphine (HOS-086193) naloxone (HOS-109490) fentanyl (HOS-086196) amiodarone (HOS-085596)

Wechselwirkungen · Zydelig

Zydelig 100 mg film-coated tablets Zydelig 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-132100 · Präparat HOS-097192

Bepridil, disopyramide, ↑ serum concentrations Clinical monitoring is recommended. lidocaine ANTI-CANCER AGENTS Tyrosine kinase inhibitors such ↑ serum concentrations Careful monitoring of the tolerance to as dasatinib and nilotinib, also these anti-cancer agents is vincristine and vinblastine recommended.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dasatinib (HOS-086217) lidocaine (HOS-108866) vinblastine (HOS-086220) bepridil (HOS-085612) vincristine (HOS-086219) disopyramide (HOS-085595) tyrosine (HOS-108875) nilotinib (HOS-086218)

Wechselwirkungen · Zydelig

Zydelig 100 mg film-coated tablets Zydelig 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7–8

HOS-132102 · Präparat HOS-097192

7 Medicinal product Expected effect of Clinical recommendation upon idelalisib on medicinal co-administration with idelalisib product levels ANTICOAGULANTS Warfarin ↑ serum concentrations It is recommended that the international normalised ratio (INR) be monitored upon co-administration and following ceasing treatment with idelalisib. ANTICONVULSANTS Carbamazepine ↑ serum concentrations Anticonvulsant medicinal product levels should be monitored. ANTIDEPRESSANTS Trazodone ↑ serum concentrations Careful dose titration of the antidepressant and monitoring for antidepressant response is recommended. ANTI-GOUT Colchicine ↑ serum concentrations Dose reductions of colchicine may be required. Idelalisib should not be co-administered with colchicine to patients with renal or hepatic impairment. ANTI-HYPERTENSIVES Amlodipine, diltiazem, ↑ serum concentrations Clinical monitoring of therapeutic felodipine, nifedipine, effect and adverse reactions is nicardipine recommended. ANTI-INFECTIVES Antifungals Ketoconazole, itraconazole, ↑ serum concentrations Clinical monitoring is recommended. posaconazole, voriconazole Antimycobacterials Rifabutin ↑ serum concentrations Increased monitoring for rifabutin- associated adverse reactions including neutropenia and uveitis is recommended. HCV protease inhibitors Boceprevir, telaprevir ↑ serum concentrations Clinical monitoring is recommended. Macrolide antibiotics Clarithromycin, telithromycin ↑ serum concentrations No dose adjustment of clarithromycin is required for patients with normal renal function or mild renal impairment (creatinine clearance [CrCl] 60-90 mL/min). Clinical monitoring is recommended for patients with CrCl < 90 mL/min. For patients with CrCl < 60 mL/min, alternative antibacterials should be considered.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) nifedipine (HOS-086289) nicardipine (HOS-090619) protease (HOS-085623) ketoconazole (HOS-084513) felodipine (HOS-108908) carbamazepine (HOS-085618) rifabutin (HOS-086262) amlodipine (HOS-086287) creatinine (HOS-086273) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) trazodone (HOS-086251) boceprevir (HOS-090617) clarithromycin (HOS-084517) colchicine (HOS-086147) warfarin (HOS-085950) posaconazole (HOS-085622)

Wechselwirkungen · Zydelig

Zydelig 100 mg film-coated tablets Zydelig 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8

HOS-132104 · Präparat HOS-097192

Clinical monitoring is recommended for telithromycin.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): telithromycin (HOS-084523)

Wechselwirkungen · Zydelig

Zydelig 100 mg film-coated tablets Zydelig 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8–9

HOS-132105 · Präparat HOS-097192

8 Medicinal product Expected effect of Clinical recommendation upon idelalisib on medicinal co-administration with idelalisib product levels ANTI-PSYCHOTICS/NEUROLEPTICS Quetiapine, pimozide ↑ serum concentrations Idelalisib should not be co-administered with quetiapine or pimozide.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) pimozide (HOS-085600)

Wechselwirkungen · Zydelig

Zydelig 100 mg film-coated tablets Zydelig 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9

HOS-132106 · Präparat HOS-097192

Alternative medicinal products, such as olanzapine, may be considered. ENDOTHELIN RECEPTOR ANTAGONISTS Bosentan ↑ serum concentrations Caution should be exercised and patients closely observed for bosentan- related toxicity. ERGOT ALKALOIDS Ergotamine, dihydroergotamine ↑ serum concentrations Idelalisib should not be co-administered with ergotamine or dihydroergotamine. GASTROINTESTINAL MOTILITY AGENTS Cisapride ↑ serum concentrations Idelalisib should not be co-administered with cisapride. GLUCOCORTICOIDS Inhaled/nasal corticosteroids: Budesonide, fluticasone ↑ serum concentrations Clinical monitoring is recommended.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): olanzapine (HOS-085937) fluticasone (HOS-108914) cisapride (HOS-085610) ergot alkaloids (HOS-108807) budesonide (HOS-086332) ergotamine (HOS-086154) bosentan (HOS-086291) dihydroergotamine (HOS-086152)

Wechselwirkungen · Zydelig

Zydelig 100 mg film-coated tablets Zydelig 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9

HOS-132107 · Präparat HOS-097192

Oral budesonide ↑ serum concentrations Clinical monitoring is recommended for increased signs/symptoms of corticosteroid effects. HMG CO-A REDUCTASE INHIBITORS Lovastatin, simvastatin ↑ serum concentrations Idelalisib should not be co-administered with lovastatin or simvastatin.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) simvastatin (HOS-086158) budesonide (HOS-086332)

Wechselwirkungen · Zydelig

Zydelig 100 mg film-coated tablets Zydelig 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9

HOS-132108 · Präparat HOS-097192

Atorvastatin ↑ serum concentrations Clinical monitoring is recommended and a lower starting dose of atorvastatin may be considered. Alternatively, switching to pravastatin, rosuvastatin, or pitavastatin may be considered. IMMUNOSUPPRESSANTS Ciclosporin, sirolimus, ↑ serum concentrations Therapeutic monitoring is tacrolimus recommended. INHALED BETA AGONIST Salmeterol ↑ serum concentrations Concurrent administration of salmeterol and idelalisib is not recommended. The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations, and sinus tachycardia.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304) rosuvastatin (HOS-086307) salmeterol (HOS-086285) tacrolimus (HOS-085202) sirolimus (HOS-085172) pravastatin (HOS-086306) pitavastatin (HOS-125743)

Wechselwirkungen · Zydelig

Zydelig 100 mg film-coated tablets Zydelig 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9–10

HOS-132110 · Präparat HOS-097192

9 Medicinal product Expected effect of Clinical recommendation upon idelalisib on medicinal co-administration with idelalisib product levels PHOSPHODIESTERASE INHIBITORS For pulmonary arterial hypertension:

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.